By 2025, innovations such as lab-on-a-chip technology, automation, and CRISPR-Cas9 gene editing are expected to enhance ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Trusted by leading innovators worldwide, ERS Genomics is committed to providing responsible and effective access to CRISPR/Cas9 technology. To support small and early-stage organizations ...

CRISPR Therapeutics is a mid-stage biotech ... Investor enthusiasm about technology and growth stocks, and the economic environment ahead, drove the momentum. After all, the artificial ...